The FDA has approved Optune Pax®, a wearable therapeutic device, for adult patients with locally advanced pancreatic adenocarcinoma when used in combination with standard chemotherapy (gemcitabine and nab-paclitaxel). This marks the first FDA approval of a new treatment option for this indication in nearly three decades. Optune Pax delivers tumour treating fields (TTFields) – low-intensity, alternating electric fields – through arrays placed on the abdomen. These fields exert physical forces that disrupt key processes in cancer cell division, leading to cancer cell death while sparing most healthy cells. The device is non-invasive and designed for regular daily use alongside chemotherapy.
The regulatory decision was based on results from the phase III PANOVA-3 trial, an international randomized study in 571 patients with unresectable, locally advanced pancreatic adenocarcinoma.1 The study met its primary endpoint, showing a statistically significant improvement in overall survival. Median survival was 16.2 months in the Optune Pax-treated group versus 14.2 months with chemotherapy alone in the intent-to-treat population (hazard ratio 0.82; p=0.039). In patients who adhered to at least 28 days of device therapy, median survival extended to 18.3 months versus 15.1 months in controls. Secondary analyses also showed higher one-year survival rates and a significant delay in progression of cancer-related pain (median 15.2 vs. 9.1 months).
“In the Phase III PANOVA-3 trial, treatment with Optune Pax resulted in a statistically significant improvement in overall survival without adding to the systemic side effects commonly associated with existing therapies. It also significantly extended time to pain progression, helping to preserve overall quality of life, which is a priority when I am treating patients living with pancreatic cancer,” said Vincent Picozzi, M.D., MMM, medical oncologist and investigator in the PANOVA-3 trial. “With FDA approval, Optune Pax has the potential to be practice changing for the treatment of patients with locally advanced pancreatic cancer.”2
Quality-of-life measures, such as global health status and symptom scores, tended to favour the Optune Pax arm, although other secondary endpoints (e.g., progression-free survival and objective response rate) did not differ appreciably between groups. Importantly, adding Optune Pax did not appear to increase systemic toxicity beyond what is expected with the chemotherapy regimen; most device-related adverse events were mild to moderate skin reactions at array sites.
Physicians and patient advocates highlighted the significance of this approval given the historically limited progress in treating locally advanced pancreatic cancer, a disease with one of the lowest long-term survival rates among common solid tumours. The FDA noted the importance of expanding patient-centred care options, including therapies that can be administered at home.
References
- Babiker HM, Picozzi V, Chandana SR. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. J Clin Oncol. 2025;43:2350–60. doi: 10.1200/JCO-25-00746.
- Novocure. U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer. Available at: https://www.novocure.com/us-fda-approves-novocures-optune-paxr-treatment-locally-advanced-pancreatic-cancer (date last accessed: 12 February 2026)
Citation: Historic first-in-class device therapy approved for locally advanced pancreatic cancer. touchONCOLOGY. 17th February, 2026.
Disclosure: This article was created by the touchONCOLOGY team utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No funding was received in the publication of this article.
Register now to receive the touchONCOLOGY newsletter!
Don’t miss out on hearing about our latest peer reviewed articles, expert opinions, conference news, podcasts and more.
